Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Hematology
Clinical Trials: Anemia
A listing of clinical trials currently looking for volunteers to enroll in Anemia studies. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Birmingham : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Birmingham : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Birmingham : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Huntsville : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Mobile : University of South Alabama Medical Center Updated
A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia
View More »
Mobile : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Arizona
Mesa : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Phoenix : Phoenix Children's Hospital Center for Cancer and Blood Disorders Updated
A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia
Phoenix : Arizona Oncology Associates, P.C.,
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Scottsdale : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Tempe : Acceleron Investigative Site
Study of ACE-536 in Healthy Postmenopausal Women
View More »
Tempe :
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis
Tucson : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Arkansas
Fayetteville : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Hot Springs : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Jonesboro : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Little Rock : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Little Rock : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
View More »
Pine Bluff :
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis
California
Anaheim : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Anaheim : Pacific Cancer Medical Inc.
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Azusa :
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis
Bakersfield : Comprehensive Blood and Cancer Center
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Culver City : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
View More »
Fountain Valley : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Fountain Valley : Compassionate Cancer Care Medical Group, Inc
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Fresno : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Fullerton : Saint Jude Heritage Medical Center
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Glendale : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Inglewood : Kaiser Permanente Updated
A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia
La Jolla : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
La Verne : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Lajolla : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Phase 1 Study of LY2787106 in Cancer and Anemia
Loma Linda : Loma Linda University Cancer Institute
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Los Angeles : Academic Medical Research Institute
A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis
Los Angeles : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Los Angeles : Childrens Hospital Los Angeles
Clinical Importance of Treating Iron Overload in Sickle Cell Disease
Los Angeles : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Los Angeles : University of California Los Angeles
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Los Angeles :
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis
Los Angeles : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Merced : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Mission Hills : North Valley Hematology Oncology Medical Group
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Modesto : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Northridge :
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis
Northridge :
Study of FG-4592 to Correct Anemia in New Dialysis Patients
Oakland : Children's Hospital & Research Center at Oakland Updated
A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia
Ontario :
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis
Orange : Children's Hospital of Orange County Updated
A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia
Orange : Medical Oncology Care Associates
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Paramount :
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis
Redondo Beach : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Redondo Beach : Cancer Care Associates Medical Group, Inc.
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
San Diego : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
San Francisco : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
San Francisco : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Santa Maria : Central Coast Medical Oncology Group
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Santa Monica : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Phase 1 Study of LY2787106 in Cancer and Anemia
Santa Rosa : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Stanford : Stanford University School of Medicine
Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia
Stanford : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Stockton : Stockton Hematology Oncology Medical Group, Inc
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Torrance : Harbor-UCLA Medical Center Updated
A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia
Vallejo : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Walnut Creek : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Westlake Village : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Yuba City :
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis
Yuba City :
Study of FG-4592 to Correct Anemia in New Dialysis Patients
Colorado
Aurora : University of Denver School of Medicine Sickle Cell Treatment & Research Center Updated
A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia
Denver : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Denver : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Grand Junction : Saint Mary Regional Cancer Center
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Connecticut
Bridgeport : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Bridgeport : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Southington : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Stamford : Hematology Oncology Associates, PC
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Florida
DeLand : Avail Clinical Research, LLC
Iron Deficiency Anemia
Miami : Pharmax Research Clinic, Inc.
Anemia- Iron Deficiency
View More »
Boynton Beach : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Coral Springs : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Daytona Beach : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Gainesville : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Holiday : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Jacksonville : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Jacksonville Beach : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Jupiter : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Lecanto : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Melbourne : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Miami : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Miami :
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis
Miami : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
New Port Richey : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Ocala : Ocala Oncology Center Pl
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Orange City : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Orlando : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Pembroke Pines :
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis
Safety Harbor : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Sarasota : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
St. Petersburg : All Children's Hospital Updated
A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia
Titusville : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Georgia
Atlanta : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Phase 1 Study of LY2787106 in Cancer and Anemia
Atlanta : Children's Healthcare of Atlanta at Egleston/Emory University Updated
A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia
Atlanta : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Augusta : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Covington : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
View More »
Stockbridge : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Thomasville : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Hawaii
Honolulu :
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis
Idaho
Boise : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Illinois
Centralia : (858) Southern Illinois Hematology Oncology
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Centralia : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Chicago : University of Illinois at Chicago Updated
A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia
Chicago : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Elk Grove Village : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
View More »
Galesburg : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Gurnee : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Joliet : Joliet Oncology-Hematology Associates, Ltd.
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Melrose Park : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Oakbrook Terrace : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Peoria : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Quincy : Quincy Medical Group
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Rockford : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Skokie : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Springfield : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Indiana
Iowa
Cedar Rapids : Iowa Blood & Cancer Care
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Council Bluffs : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Iowa City : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Iowa City : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Iowa City : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
View More »
Sioux City : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Waterloo : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Kansas
Hutchinson : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Wichita : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Wichita : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Kentucky
Hazard : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Louisville : University of Louisville School of Medicine Updated
A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia
Louisville : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Louisville :
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis
Louisville : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
View More »
Morehead : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Mt Sterling : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Paducah : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Paducah : Purchase Cancer Group
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Louisiana
Alexandria : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Alexandria : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Covington : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Lafayette : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Metairie : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
View More »
New Orleans : Sickle Cell Center of S. Louisiana, Tulane University School of Medicine Updated
A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia
New Orleans : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
New Orleans : Tulane University
Sickle Cell Disease: A Retrospective Chart Review
New Orleans : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Ruston : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Shreveport : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Slidell : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Maryland
Baltimore : Johns Hopkins University Updated
A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia
Baltimore : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Baltimore, MD :
Pharmacokinetic Study of Iron Isomaltoside 1000 Administered by 250 mg IV Bolus Injection or 500 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia
Bethesda : US National Institutes of Health - National Heart, Lung, and Blood Institute Updated
A Single Dose Study of the Safety, Blood Levels and Biological Effects of Aes-103 Compared to Placebo in Subjects With Stable Sickle Cell Disease
Bethesda : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
View More »
Cumberland : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Hagerstown : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Towson : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Massachusetts
Ayer : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Boston : Boston University Medical Center Updated
A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia
Boston : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Boston : Dana-Farber Cancer Institute
Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease
Boston : Brigham and Women's Hospital
Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease
View More »
Boston : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Boston : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Burlington : Lahey Clinic
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Haverhill : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Lexington : AMAG Pharmaceuticals, Inc.
A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia in Pediatric Subjects With Chronic Kidney Disease
Lexington : AMAG Pharmaceuticals, Inc.
A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Subjects With Dialysis Dependent Chronic Kidney Disease
Lexington : AMAG Pharmaceuticals, Inc.
A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Subjects With Nondialysis-Dependent Chronic Kidney Disease
North Dartmouth : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Worcester : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Worcester : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Michigan
Detroit : Children's Hospital of Michigan Updated
A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia
Detroit : Kresge Eye Institute
Ranibizumab for Neovascularization in Sickle Cell Retinopathy
Detroit : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Detroit : Henry Ford Health System
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Detroit :
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis
View More »
Detroit :
Study of FG-4592 to Correct Anemia in New Dialysis Patients
Detroit : Karmanos Cancer Institute
Study to Determine the Maximum Tolerated Dose, Safety and Effectiveness of Pomalidomide for Patients With Sickle Cell Disease
Grand Rapids : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Southfield : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Minnesota
Duluth : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Minneapolis : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Minneapolis : Minnesota Oncology Associates, PC
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Mississippi
Jackson : University of Mississippi Medical Center Updated
A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia
Jackson : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Tupelo : Fresenius Medical Care North America
A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis
Tupelo : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Missouri
Jefferson City : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Kansas City : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Kansas City :
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis
Kansas City : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
St. Louis : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Montana
Billings : Billings Clinic
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Kalispell : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Kalispell : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Nebraska
Grand Island : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Lincoln : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Nevada
Henderson : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Henderson : Comprehensive Cancer Centers of Nevada (TORI)
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Las Vegas : Comprehensive Cancer Center of Nevada Updated
A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia
Las Vegas : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
New Hampshire
Lebanon : (851) Dartmouth Hitchcock Medical Center
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Lebanon : Dartmouth Hitchcock Medical Center
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Manchester : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
New Jersey
Camden : Cooper University Hospital Updated
A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia
Hackensack : (857) Hackensack University Medical Center
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Livingston : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Newark : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Paterson :
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis
View More »
Sparta : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Teaneck : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Vineland : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
New Mexico
Albuquerque : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
New York
Bronx : Einstein-Montefiore Institute for Clinical & Translational Research
The Testosterone Trial - Can testosterone treatment improve unwanted effects of aging in older men?
Jamaica : Biomedical Research Alliance of New York
Anemia - cancer
Jamaica : Biomedical Research Alliance of New York
Anemia- cancer
New Hyde Park : Biomedical Research Alliance of New York
Diamond Blackfan Anemia - Adults
New York : The Rockefeller University Hospital
Entrance into the International Fanconi Anemia Registry (IFAR)
View More »
Albany : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Bronx : Bronx Lebanon Hospital Updated
A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia
Bronx : Montefiore Medical Center
Intravenous Gammaglobulin for Sickle Cell Pain Crises
Brooklyn : Brookdale University Hospital and Medical Center Updated
A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia
Brooklyn : New York Methodist Hospital - SC/Thalassemia Program Updated
A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia
Brooklyn : SUNY - Downstate Medical Center Updated
A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia
Brooklyn : The Brooklyn Hospital Center Updated
A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia
Brooklyn : Interfaith Medical Medical Center Updated
A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia
Brooklyn : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Buffalo : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Buffalo : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Cortlandt Manor : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Glens Falls : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Goshen : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Kingston : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Lake Success : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Lake Success : Monter Cancer Center, North Shore LIJ Health Systems
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Latham : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
New York : Memorial Sloan Kettering Cancer Center
Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler
New York : New York Hospital Queens
Ferric Carboxymaltose Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent CKD
New York : Mount Sinai School of Medicine
Intravenous Gammaglobulin for Sickle Cell Pain Crises
New York : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
New York :
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis
New York : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Nyack : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Rochester : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Rosedale :
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis
Staten Island : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Syracuse : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Valhalla : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Williamsville : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Williamsville :
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis
North Carolina
Wilmington : Trial Management Associates
Iron Deficiency Anemia - Have you been diagnosed with anemia or have low iron? Do you feel run down or tired all the time?
View More »
Asheville : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Burlington : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Chapel Hill : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Charlotte : Presbyterian Blume Pediatric Hematology-Oncology Clinic Updated
A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia
Charlotte : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Concord : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Durham : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Durham : Duke University Medical Center Pediatric Blood and Marrow Transplant
Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies
Durham : Duke University Medical Center
Unrelated Umbilical Cord Blood Transplantation Augmented With ALDHbr Umbilical Cord Blood Cells
Gastronia : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Goldsboro : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Hickory : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
High Point : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Huntersville : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Kinston : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Raleigh : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Washington : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Wilmington : Trial Management Associates
Ferric Carboxymaltose Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent CKD
Winston-Salem : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Phase 1 Study of LY2787106 in Cancer and Anemia
Winston-Salem : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Winston-Salem : Piedmont Hematology Oncology Associates, PLLC
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
North Dakota
Bismarck : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Ohio
Columbus : Columbus Center for Women's Health Research Updated New
Uterine Fibroids and Anemia
View More »
Akron : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Akron : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Canton : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Canton : Gabrail Cancer Center
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Cincinnati : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Cincinnati : University of Cincinnati Physician's Inc.
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Cincinnati : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Cleveland : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Cleveland : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Columbus : James Cancer Hospital
Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler
Columbus : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Columbus : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Garfield Heights : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Massillon : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Mayfield Heights : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Middletown : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Sandusky : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Toledo :
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis
Oklahoma
Oklahoma City : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Tulsa : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Oregon
Bend : Saint Charles Medical Center
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Eugene : Willamette Valley Cancer Institute and Research Center
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Portland : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Portland : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Pennsylvania
Bethlehem : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Gettysburg : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Lancaster : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Norristown : Luitpold Pharmaceuticals, Inc.
Intravenous Ferric Carboxymaltose (FCM) Versus IV Iron Sucrose or IV Iron Dextran in Treating Iron Deficiency Anemia in Women
Philadelphia : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
View More »
Philadelphia : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Philadelphia : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Pittsburgh : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Pittsburgh : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Upland : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Willow Grove : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Wynnewood : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Rhode Island
Pawtucket : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Providence : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
South Carolina
Aiken : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Anderson : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Charleston : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Charleston : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Columbia : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
View More »
Hilton Head Island : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Myrtle Beach : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Orangeburg : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Orangeburg :
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis
South Dakota
Aberdeen : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Sioux Falls : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Watertown : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Tennessee
Germantown : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Jackson : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Memphis : University of Tennessee Cancer Institute Updated
A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia
Memphis : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Memphis : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
View More »
Memphis : Universit of Tennessee
Sickle Cell Disease: A Retrospective Chart Review
Memphis : The West Clinic
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Nashville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Phase 1 Study of LY2787106 in Cancer and Anemia
Nashville : Vanderbilt University Medical Center
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Tullahoma : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Texas
San Antonio : Sun Research Institute
Have you been diagnosed with anemia or have low iron? Are you experiencing unsatisfactory results from oral iron supplements?
View More »
Abilene : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Amarillo : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Amarillo : Texas Oncology
Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match
Arlington :
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis
Beaumont : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Bedford : Texas Oncology - Bedford
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Bryan : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Corpus Chisti : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Corpus Christi : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Dallas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Phase 1 Study of LY2787106 in Cancer and Anemia
Dallas : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Dallas : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Dallas : Mary Crowley Medical Research Center
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
El Paso : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Fort Worth :
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis
Fredericksburg : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Galveston : University of Texas Medical Branch
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Garland : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Houston : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Phase 1 Study of LY2787106 in Cancer and Anemia
Houston : (855) University of Texas, MD Anderson Cancer Center
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Houston : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Houston : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Houston :
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis
Houston : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Irving : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
McAllen : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Mesquite : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Midland : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Midland : Allison Cancer Center
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Paris : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
San Antonio : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
San Antonio :
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis
San Antonio : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Sherman : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Southlake : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Sugar Land : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
The Woodlands : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Phase 1 Study of LY2787106 in Cancer and Anemia
Tyler : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Waco : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Wichita Falls : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Utah
Ogden : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Salt Lake City : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Vermont
White River Junction : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Virginia
Charlottesville : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Fairfax : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Fairfax :
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis
Midlothian : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Newport News : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
View More »
Norfolk : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Portsmouth : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Richmond : Virginia Commonwealth University Updated
A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia
Richmond : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Roanoke : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Salem : Salem VA Medical Center
Ferric Carboxymaltose Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent CKD
Salem : Oncology & Hematology Associates of Southwest Virginia, Inc
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Washington
Bremerton : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Burien : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Kirkland : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Seattle : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Seattle : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
View More »
Spokane : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Tacoma : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Tacoma : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Tacoma : Northwestern Medical Specialists, PLLC
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Vancouver : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Phase 1 Study of LY2787106 in Cancer and Anemia
Vancouver : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Yakima : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Wisconsin
Green Bay : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Javesville : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Albania
Tirane :
An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Patients With Chronic Kidney Disease in Pre-Dialysis or Dialysis
Argentina
Adrogue : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Adrogue : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Bahia Blanca : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Bahia Blanca : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Buenos Aires : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
View More »
Buenos Aires : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Buenos Aires : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Capital Federal : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Capital Federal : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Cipolletti : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Cipolletti : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Ciudad Autónoma de Buenos Aires : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Ciudad Autónoma de Buenos Aires : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Ciudad Autónoma de Buenos Aires : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Ciudad Autónoma de Buenos Aires : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Cordoba : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Cordoba : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Corrientes : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
La Plata : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
La Plata : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Lanus Este : Hospital Zonal Especializado en Oncología de Lanus
Epoetin Alfa (Hemax®) Phase IV Study in Chemotherapy Induced Anemia
Mar del Plata : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Mar del Plata : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Quilmes : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Quilmes : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Quilmes : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Quilmes : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Rosario : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Rosario : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
San Justo : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
San Miguel de Tucuman : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Santa Fe : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Santa Fe : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Australia
Adelaide : (002) Royal Adelaide Hospital
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Adelaide : Novarts Investigative Site
Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload
Box Hill : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Brisbane : Novarts Investigative Site
Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload
Geelong : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
View More »
Gosford : Gosford Hospital - Renal Unit
Ferric Carboxymaltose Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent CKD
Gosford : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Heidelberg : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Liverpool : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Melbourne : Novarts Investigative Site
Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload
New Lambton : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Prahran : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Randwick : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Reservoir : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Sydney : Novarts Investigative Site
Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload
Woolloongabba : (004) Princess Alexandra Hospital
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Austria
Austria : Austria
Safety and Efficacy Extension Study of Iron Isomaltoside 1000 (Monofer®) in Subjects With Inflammatory Bowel Disease
Graz : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Innsbruck : (151) Medizinische Universitat Innsbruck
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Innsbruck : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Innsbruck : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
View More »
Linz : (153) Krankenhaus der Elisabethinen Linz, Interne Abteilung
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Linz : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Salzburg : (154) Universitätsklinik für Innere Medizin Salzburg
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Salzburg : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Wels : (155) Klinikum Wels-Grieskirchen GmbH
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Wels : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Wien : (152) Wiener Gebietskrankenkasse-Hanusch-Krankenhaus
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Wien : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Wien : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Wien : Medizinische Universität Wien - Universitäts Klinik für Innere Medizin III
Ferric Carboxymaltose Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent CKD
Wien : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Belgium
Aalst : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Aalst : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Antwerpen : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Bonheiden : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Bonheiden : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
View More »
Brasschaat : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Brugge : (203) Algemeen Ziekenhuis Sint-Jan
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Brugge : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Brussel : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Brussels : (206) Cliniques Universitaires Saint Luc
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Bruxelles : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Charleroi : (205) Grand Hôpital de Charleroi
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Edegem : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Eupen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Genk : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Gent : University Hospital Gent - Dept. of Medicine, Nefrologie
Ferric Carboxymaltose Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent CKD
Gent : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Gilly : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Hasselt : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Huy : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Leuven : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Leuven : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Liège : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Libramont : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Liege : (201) Centre Hospitalier Universitaire Sart Tilman Liège
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Liège : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Mechelen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Mons : (204) Center Hospitalier Universitaire Ambroise Paré
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Namur : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Namur : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Oostende : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Ottignies : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Roeselare : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Roeselare : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Sint-Niklaas : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Turnhout : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Verviers : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Yvoir : (207) Cliniques Universitaires UCL de Mont-Godinne
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Brazil
Belo Horizonte : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Belo Horizonte : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Brasilia : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Brasilia : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Campinas : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
View More »
Campinas : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Campo Grande : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Campo Grande : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Curitiba : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Curitiba : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Fortaleza : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Fortaleza : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Fortaleza : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Fortaleza : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Goiania : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Goiania : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Ijui : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Ijui : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
ItajaÃ- : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Itajaí : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Londrina : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Londrina : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Passo Fundo : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Passo Fundo : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Pelotas : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Pelotas : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Porto Alegre : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Porto Alegre : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Porto Alegre : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Porto Alegre : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Recife : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Ribeirao Preto : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Ribeirao Preto : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Riberão Preto : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Riberão Preto : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Rio de Janeiro : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Rio de Janeiro : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Rio de Janeiro : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Rio De Janeiro : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
São Paulo : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
São Paulo : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Salvador : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Santo Andre : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Santo Andre : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Sao Jose dos Campos : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Sao Jose dos Campos : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Sao Paulo : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Sao Paulo : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
São Paulo : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
São Paulo : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Bulgaria
Haskovo : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Pleven : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Pleven : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Plovdiv : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Plovdiv : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
View More »
Rouse : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Sofia : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Sofia : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Sofia : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Varna : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Varna : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Veliko Tarnovo : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Canada
Edmonton : (804) University of Alberta Hospital
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Halifax : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Hamilton : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Mississauga : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Moncton : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
View More »
Montreal : (807) Maisonneuve-Rosemont Hospital
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Montreal : (808) McGill University
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Montreal : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Montreal : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Montréal : (802) Hôpital du Sacré-Coeur de Montréal
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Oshawa : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Ottawa : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Scarborough : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
St. John's : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Toronto : (801) Princess Margaret Hospital
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Toronto : (806) Sunnybrook Odette Cancer Centre
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Toronto : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Toronto : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Winnipeg : (805) Cancer Care Manitoba
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Winnipeg : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Chile
Osorno : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
San Miguel : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Santiago : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Santiago : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Temuco : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
View More »
Vina del Mar : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Vina del Mar : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
China
Beijing : Novartis Investigative Site
Safety and Efficacy of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia
Beijing : Peking University First Hospital Updated
Study of FG-4592 in Subjects With Chronic Kidney Disease in China
Beijing : Peking University First Hospital
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis in China
Chengdu : West China Hospital Updated
Study of FG-4592 in Subjects With Chronic Kidney Disease in China
Chengdu : Sichuan Provincial People's Hospital Updated
Study of FG-4592 in Subjects With Chronic Kidney Disease in China
View More »
DaLian : First affiliated hospital of Dalian medical university Updated
Study of FG-4592 in Subjects With Chronic Kidney Disease in China
Guangzhou : Department of Hematology, Liu Hua Qiao Hospital
Safety and Efficacy Study of Ex Vivo Immunotherapy for Treatment of Aplastic Anemia
Guangzhou : First Affiliated Hospital, Sun Yat-Sen University Updated
Study of FG-4592 in Subjects With Chronic Kidney Disease in China
Guangzhou : First Affiliated Hospital, Sun Yat-Sen University
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis in China
Hangzhou : Zhejiang University No 1. Hospital Updated
Study of FG-4592 in Subjects With Chronic Kidney Disease in China
Hangzhou : Zhejiang University No 1. Hospital
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis in China
Shanghai : Huashan Hospital Updated
Study of FG-4592 in Subjects With Chronic Kidney Disease in China
Shanghai : XinHua Hospital Updated
Study of FG-4592 in Subjects With Chronic Kidney Disease in China
Shanghai : Renji Hospital Updated
Study of FG-4592 in Subjects With Chronic Kidney Disease in China
Shanghai : RuiJin Hospital Updated
Study of FG-4592 in Subjects With Chronic Kidney Disease in China
Shanghai : Chang Zheng Hospital
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis in China
Shanghai : Renji Hospital
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis in China
Shanghai : RuiJin Hospital
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis in China
Shanghai : XinHua Hospital
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis in China
Shenzhen : Shenzhen People's Hospital Updated
Study of FG-4592 in Subjects With Chronic Kidney Disease in China
Shenzhen : ShenZhen People's Hospital
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis in China
Croatia
Rijeka : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Zagreb : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Czech Republic
Benesov : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Benesov u Prahy : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Brno : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Brno : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Chrudim : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
View More »
Horovice : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Jilemnice : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Karlovy Vary : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Kladno : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Kyjov : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Novy Jicin : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Olomouc : (251) Fakultni nemocnice Olomouc, hemato-onkologicka klinika
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Olomouc : (252) Fakultni nemocnice Olomouc, hemato-onkologicka klinika
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Ostrava-Poruba : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Pardubice : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Plzen : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Praha : (253) Vseobecna Fakultni Nemocnice v Praze
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Praha : (254) Ustav Hematologie a Krevni Transfuze
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Praha : Institut klinicke a experimentalni mediciny (IKEM) - Klinika nefrologie
Ferric Carboxymaltose Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent CKD
Praha 10 : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Praha 10 : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Praha 4 : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Praha 4 : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Praha 4 - Nusle : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Praha 6 : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Praha 8 : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Praha 8 : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Pribram 8 : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Slavkov u Brna : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Sternberk : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Denmark
Aalborg : Research Site
Iron Oligosaccharide in Inflammatory Bowel Disease Subjects With Iron Deficiency Anaemia
Aarhus : Aarhus University Hospital
Iron Substitution After Upper Gastro-Intestinal Bleeding
Århus : Research Site
Iron Oligosaccharide in Inflammatory Bowel Disease Subjects With Iron Deficiency Anaemia
Copenhagen : Rigshospitalet University Hospital - Department of Nephrology
Ferric Carboxymaltose Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent CKD
Copenhagen : Research Site
Iron Oligosaccharide in Inflammatory Bowel Disease Subjects With Iron Deficiency Anaemia
View More »
Frederiksberg : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Glostrup : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Hellerup : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Herlev : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Holbaek : Pharmacosmos
A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) as Mono Therapy (Without Erythropoeisis Stimulating Agents) in Comparison With Oral Iron Sulfate in Subjects With Non-myeloid Malignancies Associated With Chemotherapy Induced Anaemia (CIA)
Holbaek : Pharmacosmos
Iron Isomaltoside 1000 (Monofer®) in Non-Dialysis Dependent Chronic Kidney Disease and With Renal-Related Anaemia
København Ø : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
København S : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
København Ø : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
København S : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Næstved : Næstved Sygehus
A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) as Mono Therapy (Without Erythropoeisis Stimulating Agents) in Comparison With Oral Iron Sulfate in Subjects With Non-myeloid Malignancies Associated With Chemotherapy Induced Anaemia (CIA)
Odense : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Roskilde : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Svendborg : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Egypt
Cairo :
A Study of Mircera (C.E.R.A.) in Patients With Pre-Dialysis Chronic Renal Anemia
Mansoura :
A Study of Mircera (C.E.R.A.) in Patients With Pre-Dialysis Chronic Renal Anemia
Estonia
Pärnu : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Pärnu : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Tallinn : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Tallinn : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Finland
Helsinki :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Kajaani :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Pietarsaari :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
France
Aix en Provencence cedex 01 : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Amiens : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Angers Cedex 9 : (307) Center Hospitalier Universitaire d' Angers
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Aubagne : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Besançon Cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
View More »
Bobigny : (304) Hôpital Avicenne - Service d'Hématologie Clinique
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Bourg en Bresse : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Brive la Gaillarde : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Carcassonne : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Creteil : Hôpital Henri Mondor
Safety Study of MP4CO in Adult Sickle Cell Patients
Créteil : Henri Mondor University Hospital
Rituximab in Auto-Immune Hemolytic Anemia
Draguignan Cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Grenoble Cedex 9 : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
La Tronche : (303) Hopital A. Michallon
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Lille :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Lille Cedex : (305) Hôpital Claude Hurlezk service des maladies du sang
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Lille Cedex : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Longjumeau cedex 1 : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Marseille : (306) Institut Paoli Calmettes Centre Regional de Lutte Contre le Cancer
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Mont de Marsan : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Montauban cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Montfermeil : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Montpellier : Hôpital Lapeyronie
Ferric Carboxymaltose Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent CKD
Montpellier cedex 05 : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Orléans : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Paris : Research Facility
Efficacy and Safety of Hematide™ Injection in the Treatment of Anemia in Patients With Chronic Kidney Disease
Paris : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Paris Cedex 14 : (302) Groupe hospitalier Cochin Saint-Vincent de Paul
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Paris Cedex 20 : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Pessac Cedex : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Poitiers : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Pontoise Cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Pontoise Cedex : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Prigny : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Reims : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Reims Cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Rouen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Saint Grégoire cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Saint Herblain : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Saint Quentin : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Soissons : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Soissons :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Suresnes :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Toulouse Cedex 09 : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Vichy cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Villefranche Sur Saone Cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Germany
Alsfeld :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Alzey :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Augsburg : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Bad Berka : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Bad Nauheim :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
View More »
Bad Wildungen :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Bamberg : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Bayreuth :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Berlin : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Berlin : Vivantes Klinikum Neukölln, Klinikum für Geburtsmedizin
Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Women
Berlin :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Berlin : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Bernkastel-Kues : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Bremerhaven : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Coesfeld : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Darmstadt :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Dresden : (359) Gemeinschaftspraxis fur Hamatologie un Onkologie
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Duisburg : (352) Sankt Johannes Hospital Duisburg
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Düsseldorf : (356) Universitätsklinikum Düsseldorf, Klinik für Hämatologie, Onkologie und Klinische Immunologie
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Düsseldorf : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Erlangen : Research Facility
Efficacy and Safety of Hematide™ Injection in the Treatment of Anemia in Patients With Chronic Kidney Disease
Essen :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Frankfurt : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Georgsmarienhütte : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Georgsmarienhütte : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Gutersloh :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Hagenow :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Halle/ Saale : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Halle/Saale : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Hamburg :
A Study of Intravenous Mircera for the Treatment of Anemia in Pediatric Patients on Hemodialysis.
Hamburg : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Hamburg : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Hamm :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Hannover : (354) Medizinische Hochschutle Hannover
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Heidelberg : (357) Universitat Heidelberg
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Hemer : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Herne :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Herzberg :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Homberg :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Hurth-Hermulheim :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Ingelheim : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Köln : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Köln : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Köln-Merheim : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Kaiserslautern :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Kassel : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Koln :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Köln : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Köln : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Köln-Merheim : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Leipzig : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Leverkusen :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Leverkusen : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Lüdenscheid :
Observational Study to Investigate the Long-term Effects of MIRCERA in Clinical Routine
Ludwigslust :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Luebeck :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
München : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Magdeburg :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Mainz : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Mannheim : (353) Universitatsklinikum Mannheim
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Mannheim : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Marburg : Klinik Für Frauenheilkunde und Geburtshilfe Universitätsklinikum Marburg
Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Women
Marburg : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Mayen :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Mettmann :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Moers : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Muenster : University Hospital Muenster
Intravenous Ferric Carboxymaltose (Ferinject) in Patients Undergoing Orthopaedic Surgery
Munchen : (355) Klinikum rechts der Isar, Technische Universitat Munchen
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Munchen :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
München : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
München : Perinatalzentrum, Klinikum Innenstadt LMU
Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Women
Nürnberg : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Neunkirchen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Nürnberg : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Potsdam :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Quedlinburg :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Rotenburg (Wümme) : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Saarlouis :
An Observational Study of Mircera (Methoxy Polyethylene Glycol-epoetin Beta) in Patients With Renal Anemia
Saarlouis :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Schwedt : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Solingen :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Stralsund : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Stuttgart : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Ulm : University Hospital Ulm
Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler
Ulm : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Viersen : Dr. med. Sven Herrnberger
MONITOR-CKD5 - Multi-level Evaluation of Anaemia Treatment, Outcomes, and Determinants in Chronic Kidney Disease Stage 5
Würselen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Weisbaden :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Würselen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Würzburg : Universitätsklinikum Würzburg - Medizinische Klinik und Poliklinik I ,
Ferric Carboxymaltose Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent CKD
Greece
,Athens : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Athens :
A Study of MIRCERA for the Intrapetient Variability of Hemoglobin Levels in Patients With Chronic Renal Anemia (RIVAL)
Athens : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Chania : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Larissa : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
View More »
Patra :
A Study of MIRCERA for the Intrapetient Variability of Hemoglobin Levels in Patients With Chronic Renal Anemia (RIVAL)
Piraeus : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Thessaloniki : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Thessaloniki : General Hospital of Thessaloniki - Department of Nephrology
Ferric Carboxymaltose Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent CKD
Hong Kong
Hong Kong : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Hong Kong : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Kowloon : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Sha Tin : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Tuen Mun : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Hungary
Baja : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Debrecen : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Esztergom : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Gyor : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Kaposvar : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
View More »
Pecs : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Szekszard : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Szombathely : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Zalaegerszeg : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
India
Ahmedabad :
A Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) for the Treatment of Chronic Renal Anaemia in Patients With Diabetic Nephropathy
Ahmedabad : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Ahmednagar : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Ahmednagar : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Aurangabad : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
View More »
Aurangabad : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Bangalore : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Bangalore : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Bikaner : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Chennai : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Chennai : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Coimbatore : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Delhi :
A Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) for the Treatment of Chronic Renal Anaemia in Patients With Diabetic Nephropathy
Gurgaon : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Hyderabad :
A Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) for the Treatment of Chronic Renal Anaemia in Patients With Diabetic Nephropathy
Hyderabad : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Hyderabad : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Hyderabad : Research Site
Iron Oligosaccharide in Inflammatory Bowel Disease Subjects With Iron Deficiency Anaemia
Hyderabad : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Hyderabad : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Jaipur : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Jaipur : Research Site
Iron Oligosaccharide in Inflammatory Bowel Disease Subjects With Iron Deficiency Anaemia
Kochi : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Kolkata : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Kolkata : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Lucknow : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Lucknow : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Ludhiana : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Mangalore : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Miraj : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Miraj : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Mumbai :
A Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) for the Treatment of Chronic Renal Anaemia in Patients With Diabetic Nephropathy
Mumbai : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Mumbai : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Mumbai : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Mumbai : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Nagpur : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Nagpur : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Nashik : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Nashik : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Nashik : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Nashik : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Nasik : Research Site
Iron Oligosaccharide in Inflammatory Bowel Disease Subjects With Iron Deficiency Anaemia
New Delhi :
A Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) for the Treatment of Chronic Renal Anaemia in Patients With Diabetic Nephropathy
New Delhi : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
New Delhi : Research Site
Iron Oligosaccharide in Inflammatory Bowel Disease Subjects With Iron Deficiency Anaemia
New Delhi : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Pune :
A Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) for the Treatment of Chronic Renal Anaemia in Patients With Diabetic Nephropathy
Pune : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Pune : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Pune : Research Site
Iron Oligosaccharide in Inflammatory Bowel Disease Subjects With Iron Deficiency Anaemia
Pune : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Pune : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Ireland
Dublin : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Galway :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Israel
Ashkelon : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Askelon : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Beer Sheva : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Givatayim : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Hadera : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
View More »
Hadera : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Haifa : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Holon : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Jerusalem : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Jerusalem : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Jerusalem : Hadassah Medical Organization
Safety and Efficacy of Sustained Erythropoietin Therapy
Jerusalem : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Kfar Saba : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Kfar Saba : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Petach Tikva : (404) Rabin Medical Center
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Poria Eylit : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Rehovot : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Safed : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Tel Aviv : (401) Tel Aviv Sourasky Medical Center
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Tel Aviv : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Tel Aviv : Tel Aviv Sourasky Medical Center
Safety and Efficacy of Sustained Erythropoietin Therapy
Tel Hashomer : (402) Chaim Sheba Medical Center
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Italy
Albano Laziale : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Alessandria : (456) Azienda Ospedaliera SS. Antonio E. Biagio E. Cesare Arrigo di Allessandria
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Ancona :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Ancona : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Anzio :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
View More »
Bergamo : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Bologna : (460) Instituto Di Ematologia ED Oncologia Medica "LA Seragnoli" Policlinico S. Orsola Malpighi
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Cagliari : (461) Ospedale R. Binaghi
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Cagliari : (457) Azienda Ospedaliero-Universitaria di Cagliari
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Catania : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Catania :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Cefalù : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Cefalù : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Cesenatico (FC) : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Chieri :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Cortona : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Eboli : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Faenza : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Ferrara : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Firenze : (462) Azienda Ospedalieo - Universitaria Careggi
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Firenze : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Forlì : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Lecce : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Lecco : Azienda Ospedaliera Provinciale Di Lecco Ospedale
Ferric Carboxymaltose Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent CKD
Lecco : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Lugo : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Mantova :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Meldola (FC) : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Messina : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Milano : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Milano :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Naples : (458) AORN A. Cardarelli
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Naples :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Napoli : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Napoli : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Napoli :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Napoli : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Nocera :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Nola :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Orbassano : (459) Azienda Sanitaria Ospedaliera "San Luigi Gonzaga"
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Padova : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Palermo : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Pavia :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Ravenna : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Rionero in Vulture : (455) IRCCS Centro di Riferimento Oncologico di Basilicata di Rionero in Vulture
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Roma : (452) Azienda Ospedaliera Universitaria Policlinico Tor Vergata
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Roma : (453) Azienda Policlinico Umberto l di Roma
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Roma : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Roma : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Roma : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Rome :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
S. Angelo dei Lombardi :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
San Giovanni Rotondo (FG) : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Santa Maria :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Soverato :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Torino : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Torino :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Torino : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Udine : (451) Azienda Ospedaliero Universitaria "S. Maria della Misericordia" di Udine
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Udine : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Zingonia-Oslo Sotto :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Jamaica
Japan
Fukuoka : Novartis Investigative Site
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Hiroshima : (908) Hiroshima University Hospital
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Hiroshima : Novartis Investigative Site
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Hyogo : Novartis Investigative Site
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Isehara : (904) Tokai University School of Medicine
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
View More »
Ishikawa : Novartis Investigative Site
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Kamogawa : (910) Kameda General Hospital
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Kumamoto : Novartis Investigative Site
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Kyoto : Novartis Investigative Site
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Nagasaki : (909) Nagasaki University Hospital
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Nagasaki : Novartis Investigative Site
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Nagoya : (906) National Hospital Organization Nagoya Medical Center
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Nagoya : Novartis Investigative Site
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Osaka : (907) Osaka Red Cross Hospital
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Osaka : Novartis Investigative Site
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Sapporo : Novartis Investigative Site
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Sendai : (911) Tohoku University Hospital
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Shibuya : (902) Japanese Red Cross Medical Center
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Shimotsuga-gun : Novartis Investigative Site
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Shimotsuke : (901) Jichi Medical University Hospital
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Shinagawa : (903) Kanto Medical Center NTT EC
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Tochigi : Novartis Investigative Site
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Tokyo : Novartis Investigative Site
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Toyama : Novartis Investigative Site
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Korea, Republic of
Seoul : NHIC Ilsan Hospital
Study of Erythropoietin (EPO) Administration Schedule
Latvia
Daugavpils : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Daugavpils : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Riga : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Riga : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Valmiera : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
View More »
Ventspils : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Lithuania
Alytus : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Kaunas : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Klaipeda : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Siauliai : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Vilnius : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
View More »
Vilnius : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Luxembourg
Differdange : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Luxembourg : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Macedonia, The Former Yugoslav Republic of
Prilep :
An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) as Maintenance Treatment in Patients With Chronic Renal Anemia on Haemodialysis
Stip :
An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) as Maintenance Treatment in Patients With Chronic Renal Anemia on Haemodialysis
Mexico
Aguascalientes : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Aguascalientes : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Aguascalientes : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Colima : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Cuernavaca : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
View More »
D.f. : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Distrito Federal : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Distrito Federal : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Guadajalara : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Guadalajara : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Guadalajara : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Guadalajara : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Jalapa : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Merida : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Merida : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Merida : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Merida : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Mexico : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Mexico City : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Mexico City : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Mexico City : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Mexico City : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Mexico City : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Monterrey : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Monterrey : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Puebla : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Puebla : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Queretaro : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Queretaro : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Queretaro : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Saltillo : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Saltillo : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
San Luis Potosi : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
San Luis Potosi : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
San Luis Potosi : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Tijuana : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Morocco
Casablanca :
A Study of Once Monthly Subcutaneous Mircera in Dialysis Patients With Chronic Renal Anemia
Netherlands
Almelo : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Amersfoort : Meander Medisch Centrum - Locatie Amersfoort Lichtenberg
Ferric Carboxymaltose Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent CKD
Amstelveen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Arnhem : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Breda : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
View More »
Breda : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Delft : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Den Haag : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Deventer : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Dordrecht : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Enschede : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Groningen : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Haarlem : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Harderwijk : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Heerlen : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Hoorn : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Leiderdorp : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Purmerend : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Rotterdam : Erasmus Medical Center
Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler
Rotterdam : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Rotterdam : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Vlissingen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Zutphen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Norway
Ã…lesund : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Ålesund : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Arendal : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Oslo : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Skien : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
View More »
Stavanger : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Trondheim : St. Olav's Hospital
Ferric Carboxymaltose Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent CKD
Pakistan
Lahore :
An Observational Study of Mircera (Methoxy Polyethylene Glycol-epoetin Beta) in Anemic Patients With Chronic Kidney Disease (NORM)
Peshawar :
An Observational Study of Mircera (Methoxy Polyethylene Glycol-epoetin Beta) in Anemic Patients With Chronic Kidney Disease (NORM)
Philippines
Baguio City : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Cebu : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Davao City : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Manila : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Metro Manila : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
View More »
Pasig City : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Quezon City : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Taguig City : FNRI
Nutrient Fortified Oat Drink
Poland
Bialystok : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Bialystok : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Bydgoszcz : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Choszczno : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Gdansk : (504) Katedra I Klinika Hematologii z Osrodkiem Transplantacji Szpiku Kostnego AM; SPSK nr 1
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
View More »
Gdansk : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Gdansk : Uniwersyteckie Centrum Kliniczne - Katedra i Klinika Nefrologii, Transplantologii i Chorob Wewnetrznych
Ferric Carboxymaltose Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent CKD
Gdansk : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Gdansk : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Gdynia : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Glucholazy : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Golub-Dobrzyn : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Koszalin : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Krakow : Novartis Investigative Site
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Krakow : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Legnica : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Lodz : (502) Lodzki Uniwersytet Medyczny, Klinika Hematologii
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Lodz : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Lodz : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Lomza : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Lubin : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Lublin : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Lublin : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Olsztyn : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Olsztyn : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Pabianice :
A Study of All-Cause Mortality and Cardiovascular Morbidity in CKD Patients on Dialysis and Those Not on Renal Replacement Therapy Receiving Mircera or Reference ESAs.
Poznan :
A Study of All-Cause Mortality and Cardiovascular Morbidity in CKD Patients on Dialysis and Those Not on Renal Replacement Therapy Receiving Mircera or Reference ESAs.
Poznan : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Rzeszow : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Skierniewice :
A Study of All-Cause Mortality and Cardiovascular Morbidity in CKD Patients on Dialysis and Those Not on Renal Replacement Therapy Receiving Mircera or Reference ESAs.
Stalowa Wola : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Suwalki : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Szczecin : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Szczecin : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Walbrzych : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Warsaw : (503) Instytut Hematologii i Tansfuzjologii, Klinika Hematologii
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Warszawa : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Warszawa : Novartis Investigative Site
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Warszawa : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Warszawa : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Wroclaw : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Wroclaw : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Wroclaw : Novartis Investigative Site
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Wroclaw : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Zabrze : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Zamosc : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Zielona Gora : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Portugal
Coimbra : (553) Hospitais da Universidade de Coimbra
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Coimbra : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Evora : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Faro : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Leiria : Eurodial clinic - Rua da Carrasqueira
Ferric Carboxymaltose Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent CKD
View More »
Lisboa : (552) Instituto Português de Oncologia de Lisboa de Francisco Gentil, EPE
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Lisboa : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Lisbon : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Porto : (551) Hospital Geral de Santo Antonio
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Setúbal : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Vila Nova de Gaia :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Puerto Rico
San Juan : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
San Juan : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
San Juan : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Romania
Alba Iulia : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Arad : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Bacau : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Baia-Mare : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Brasov : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
View More »
Brasov : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Bucharest : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Bucharest : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Bucuresti : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Bucuresti : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Cluj Napoca : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Cluj-Napoca : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Craiova : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Craiova : Spitalul Clinic Judetean de Urgenta Craiova
Ferric Carboxymaltose Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent CKD
Lasi : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Oradea : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Oradea : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Ramnicu Valcea : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Suceava : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Targu Mures : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Targu Mures : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Timisoara : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Timisoara : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Timisoara : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Russian Federation
Arkhangelsk : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Ekaterinburg : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Ivanovo : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Kirov : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Krasnodar : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
View More »
Kursk : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Lipetsk :
A Study of the Quality of Life and Treatment Response to Once Weekly NeoRecormon (Epoetin Beta) Treatment in Anemic Patients With Solid and Lymphoid Malignancies.
Moscow : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Moscow : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Moscow : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Moscow : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Novosibirsk : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Obninsk : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Orenburg : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Penza : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Petrozavodsk :
A Study of the Quality of Life and Treatment Response to Once Weekly NeoRecormon (Epoetin Beta) Treatment in Anemic Patients With Solid and Lymphoid Malignancies.
Saint Petersburg : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Saint Petersburg : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Saint Petersburg : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Saint-Petersburg : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Salekhard :
A Study of the Quality of Life and Treatment Response to Once Weekly NeoRecormon (Epoetin Beta) Treatment in Anemic Patients With Solid and Lymphoid Malignancies.
Sankt-Petersburg : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Saratov : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
St Petersburg :
A Study of the Quality of Life and Treatment Response to Once Weekly NeoRecormon (Epoetin Beta) Treatment in Anemic Patients With Solid and Lymphoid Malignancies.
St Petersburg : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
St Petersburg : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
St. Petersburg : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Stavropol' : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
UFA :
A Study of the Quality of Life and Treatment Response to Once Weekly NeoRecormon (Epoetin Beta) Treatment in Anemic Patients With Solid and Lymphoid Malignancies.
Ufa : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Volgograd : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Voronezh : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Yaroslavl : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Serbia
Belgrade : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Belgrade : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Gornji Matejevac : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Kragujevac : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Krgujevac : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
View More »
Sremska Kamenica : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Zemun : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Singapore
Singapore : Novartis Investigative Site
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Slovakia
Banska Bystrica : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Bardejov : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Bratislava : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Bratislava : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Kosice : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
View More »
Kosice : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Lucenec : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Nitra : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Presov : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Sala : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Trstena : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Zvolen : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Slovenia
Golnik : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
South Africa
Bloemfontein : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Boksburg : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Cape Town : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Cape Town : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Durban : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
View More »
Durban : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Durban : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Johannesburg : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Johannesburg : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Overport : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Parow : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Polokwane : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Pretoria : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Somerset West : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Somerset West : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Soweto : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Worcester : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Worcester : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Spain
Alicante : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Alicante : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Badalona : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Badalona : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Barcelona : (607) Hospital Clinic i Provincial - Servicio de Hematologia y Hemoterapia
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
View More »
Barcelona : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Barcelona : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Barcelona :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Barcelona : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Barcelona : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Barcelona : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Benalmadena :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Benidorm : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Benidorm : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
El Palmar : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Fuenlabrada :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Galdakao : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Granada : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Granada : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Granada : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Granada : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Jaén : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Las Palmas de Gran Canaria : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
L'Hospitalet de Llobregat : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Madrid : (606) Hospital Universitario La Paz
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Madrid : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Madrid : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Majadhonda : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Malaga : (603) Hospital Clinico Universitario Virgen de la Victoria
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Palma de Mallorca : (602) Hospital Son Llatzer
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Pontevedra : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Sabadell : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Sabadell : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Salamanca : (605) Hospital Universitario de Salamanca, Hospital Clinico, Sevicio de Hematologia
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Salamanca : Novartis Investigative Site
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Sant Cugat del Valles :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Santander : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Santiago de Compostela : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Sevilla : (608) Hospital Universitario Virgen del Rocio
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Valencia : (601) Hospital La Fe, Servicio de Hematologia
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Valencia : Novartis Investigative Site
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Valencia : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Valencia : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Xativa :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Sweden
Falun : Kvinnokliniken, Falu lasarett
Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Women
Göteborg : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Göteborg : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Huddinge :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Linkoping :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
View More »
Lund : Kvinnokliniken, University Hospital
Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Women
Mölndal : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Malmö : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Malmö : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Mölndal : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Stockholm : Kvinnokliniken, Karolinska University Hospital
Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Women
Stockholm : Karolinska Universitetssjukhuset Huddinge, Centrum för fostermedicin KK
Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Women
Stockholm : Karolinska University Hospital
Ferric Carboxymaltose Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent CKD
Stockholm : Department of Medicine, St Görans Hospital (Capio St Görans Sjukhus)
Ferric Carboxymaltose in Subjects With Functional Iron Deficiency Undergoing Chemotherapy
Sundsvall : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Umeå : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Umeå : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Uppsala : University Hospital, Dept of obstetrics and gynecology Uppsala
Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Women
Uppsala : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Switzerland
Aarau : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Aarau : Kantonsspital Aarau - Nephrology Department
Ferric Carboxymaltose Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent CKD
Basel : Universitätsspital Basel, Geburtshilfe und Schwangerschaftsmedizin Frauenklinik
Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Women
Bern : Humboldtstrasse
Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Women
Bern : Inselspital, Department of Obstetrics and Gynecology
Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Women
View More »
Chur : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Genève : HUG, Département de Gynécologie-Obstétrique
Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Women
Lausanne : CHUV, Département de Gynécologie-Obstétrique
Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Women
Lugano : OR Lugano, sede Ospedale Civico, Clinica ginecologia ostetricia
Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Women
Sursee : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Zurich : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Zurich : Universitätsspital Zürich
Intravenous Ferric Carboxymaltose (Ferinject®) With or Without Erythropoietin in Patients Undergoing Orthopaedic Surgery
Zürich : Universitätsspital Zürich, Departement Frauenheilkunde
Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Women
Taiwan
Changhua City : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Kaohsiung : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Taichung : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Taichung City : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Tainan : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Turkey
Adana : Cukurova University Hospital
Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Women
Adana : Novartis Investigative Site
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Ankara : Novartis Investigative Site
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Ankara : Ankara University - School of Medicine
Ferric Carboxymaltose Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent CKD
Istanbul : Zeynep Kamil Hospital, Arakiyeci Haci Mehmet Mahallesi.
Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Women
View More »
Istanbul : Istanbul Uni. Ist. Med. Faculty
Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Women
Istanbul : Novartis Investigative Site
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Izmir : Novartis Investigative Site
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Ukraine
Chernivtsi : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Dnipropetrovsk : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Kiev : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Kirovograd : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Kyiv : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
View More »
Lutsk : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Lviv : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Sumy : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Uzhgorod : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
United Kingdom
Birmingham : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Birmingham : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Bournemouth : (707) Royal Bournemouth Hospital
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Bradford : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Brighton : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
View More »
Cambridge : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Cardiff : (706) University Hospital of Wales
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Cardiff : Cardiff University
Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler
Cottingham : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Coventry : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Coventry : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Derby : Research Facility
Efficacy and Safety of Hematide™ Injection in the Treatment of Anemia in Patients With Chronic Kidney Disease
Dorechester : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Glasgow : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Glasgow : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Harrow : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Hull : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Kirkcaldy : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Leeds : (704) Saint James' University Hospital
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Leeds : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Leeds : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Leicester : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Leicester : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Liverpool : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
London : (708) Barts and the London NHS Trust
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
London : (702) King's College Hospital
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
London : Research Facility
Efficacy and Safety of Hematide™ Injection in the Treatment of Anemia in Patients With Chronic Kidney Disease
London : King's College Hospital
Ferric Carboxymaltose Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent CKD
London :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
London : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
London : Guy's Hospital
Safety Study of MP4CO in Adult Sickle Cell Patients
London : King's College London
Safety Study of MP4CO in Adult Sickle Cell Patients
London : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Manchester : (701) Christie Hospital
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Manchester : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Newcastle Upon Tyne : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Oxford : (705) John Radcliffe Hospital
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Poole : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Romford : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Salford : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Shrewsbury : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Stevenage : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Stoke On Trent : Research Site
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
Worthing : Worthing Hospital
Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Crohn's Disease (AEGIS-2)
Worthing : Worthing Hospital
Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Ulcerative Colitis (AEGIS-1)
York : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
United States
Washington : Howard University Hospital & Howard University Updated
A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia
Washington : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Washington : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
